Immunoglobulin A nephropathy (IgAN)
Effect of iptacopan on proteinuria and complement biomarkers over time in IgA nephropathy
Jonathan Barratt, Brad H. Rovin, Hong Zhang, Dana V. Rizk, Naoki Kashihara, Bart D. Maes, Hernán Trimarchi, Ben Sprangers, Matthias Meier, Dmitrij Kollins, Guido Junge, Julie Milojevic, Olympia Papachristofi, Vlado Perkovic
Prognosis, dialysis and transplantation in patients with immunoglobulin A nephropathy: Evidence from real-world data
Dario Roccatello, Michel Kroes, Serge Smeets, Aneesh Thomas George, Luis Prieto, Jonathan de Courcy, Jade Garratt-Wheeldon, Li Yao
Symptom burden of patients with IgA Nephropathy in a real world setting across geographies
Richard Lafayette, Serge Smeets, Julia Kattlun, Aneesh Thomas George, Carolina Aldworth, Clare Proudfoot, Weijia Wang, Jonathan de Courcy, Li Yao, Dario Roccatello
Persistence of signs and symptoms in treated patients with IgAN: Evidence from real-world data
Richard Lafayette, Michel Kroes, Carolina Aldworth, Luis Prieto Rodriguez, Aneesh Thomas George, Weijia Wang, Jonathan de Courcy, Keisha Golden, Emma Chatterton, Li Yao, Dario Roccatello
IgA nephropathy and risks of kidney and cardiovascular events and death: The KNIGHT study
Thida C. Tan, Rishi V. Parikh, Ajit Mahapatra, Robert Perkins, Alan S. Go
The patient journey for immunoglobulin A nephropathy: Diagnostic delay and change in kidney function from first clinical sign
Robert Perkins, Elyse Swallow, Weijia Wang, Emily Gao, Steve Olson, Jennifer Sung, Ha Nguyen, Danielle Peterson, Emma Billmyer, Alexander Chang
Complement 3 glomerulopathy (C3G)
An open-label, non-randomized extension study to evaluate long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy: Interim analysis of a Phase 2 study
Carla M Nester, Ute Eisenberger, Alexandre Karras, Moglie le Quintrec-Donnette, Liz Lightstone, Manuel Praga, Giuseppe Remuzzi, Maria Jose Soler, Junhao Liu, Matthias Meier, Ronda Tawfik, Guido Junge, Andrea Biondani, Angelo J Trapani, Nicholas J A Webb, Edwin K Wong
Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN)
A multicenter, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy and safety of iptacopan in idiopathic immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN)
Udaykiran Veldandi, David Kavanagh, Marina Vivarelli, Andrew Bomback, Yaqin Wang, Karolina Bogdanowicz, Nicholas J A Webb, Matthias Meier, Richard JH Smith
Lupus nephritis (LN)
An adaptive, dose-exploration, Phase 2 trial evaluating efficacy and safety of iptacopan in combination with standard-of-care with and without oral corticosteroids in active lupus nephritis
Udaykiran Veldandi, Hans-Joachim Anders, Tak Mao Chan, David Jayne, Piyush Mahajan, Janina Linnik, Nicholas J A Webb, Matthias Meier, Brad H. Rovin
General
Can young children swallow multiple coated mini-tablets? Results from an open-label, single-dose crossover study
Isabelle Sessler, Nicholas J A Webb, Philipp Lustenberger, Rama Sivasubramanian, Giulio Loforese, Juliane Münch, Hans Martin Bosse, Viviane Klingmann
Absorption and disposition of a first-in-class alternative complement pathway factor B inhibitor: Iptacopan
Robert Schmouder, Bharti Shah, Melissa Hackling, Alexander David James, Prasanna Kumar Nidamarthy, Kenneth Kulmatycki
Assessment of drug interactions with iptacopan
Robert Schmouder, Bharti Shah, Amanda Taylor, Prasanna Kumar Nidamarthy, Kenneth Kulmatycki
Alternative complement pathway pharmacodynamics of iptacopan
Robert Schmouder, Guido Junge, Julie Milojevic, Prasanna Kumar Nidamarthy, Kenneth Kulmatycki